Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Syndax Pharmaceuticals stock | $25.75

Own Syndax Pharmaceuticals stock in just a few minutes.

Fact checked

Syndax Pharmaceuticals, Inc is a biotechnology business based in the US. Syndax Pharmaceuticals shares (SNDX) are listed on the NASDAQ and all prices are listed in US Dollars. Syndax Pharmaceuticals employs 35 staff and has a trailing 12-month revenue of around USD$1.5 million.

How to buy shares in Syndax Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Syndax Pharmaceuticals. Find the stock by name or ticker symbol: SNDX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Syndax Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$25.75, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Syndax Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Syndax Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Syndax Pharmaceuticals share price

Use our graph to track the performance of SNDX stocks over time.

Syndax Pharmaceuticals shares at a glance

Information last updated 2020-12-02.
Latest market closeUSD$25.75
52-week rangeUSD$6.32 - USD$23.98
50-day moving average USD$19.52
200-day moving average USD$16.6628
Wall St. target priceUSD$24.6
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.357

Buy Syndax Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Forex
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, ETFs
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Bonds
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Syndax Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Syndax Pharmaceuticals price performance over time

Historical closes compared with the close of $25.75 from 2020-12-09

1 week (2021-01-11) N/A
1 month (2020-12-22) 7.25%
3 months (2020-10-18) N/A
6 months (2020-07-18) N/A
1 year (2020-01-18) N/A
2 years (2019-01-18) N/A
3 years (2018-01-18) N/A
5 years (2016-01-18) N/A

Syndax Pharmaceuticals financials

Revenue TTM USD$1.5 million
Gross profit TTM USD$1.5 million
Return on assets TTM -32.15%
Return on equity TTM -75.83%
Profit margin 0%
Book value $3.398
Market capitalisation USD$902 million

TTM: trailing 12 months

Shorting Syndax Pharmaceuticals shares

There are currently 4.6 million Syndax Pharmaceuticals shares held short by investors – that's known as Syndax Pharmaceuticals's "short interest". This figure is 5.1% up from 4.4 million last month.

There are a few different ways that this level of interest in shorting Syndax Pharmaceuticals shares can be evaluated.

Syndax Pharmaceuticals's "short interest ratio" (SIR)

Syndax Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Syndax Pharmaceuticals shares currently shorted divided by the average quantity of Syndax Pharmaceuticals shares traded daily (recently around 748421.46341463). Syndax Pharmaceuticals's SIR currently stands at 6.15. In other words for every 100,000 Syndax Pharmaceuticals shares traded daily on the market, roughly 6150 shares are currently held short.

However Syndax Pharmaceuticals's short interest can also be evaluated against the total number of Syndax Pharmaceuticals shares, or, against the total number of tradable Syndax Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Syndax Pharmaceuticals's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Syndax Pharmaceuticals shares in existence, roughly 110 shares are currently held short) or 0.1237% of the tradable shares (for every 100,000 tradable Syndax Pharmaceuticals shares, roughly 124 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Syndax Pharmaceuticals.

Find out more about how you can short Syndax Pharmaceuticals stock.

Syndax Pharmaceuticals share dividends

We're not expecting Syndax Pharmaceuticals to pay a dividend over the next 12 months.

Syndax Pharmaceuticals share price volatility

Over the last 12 months, Syndax Pharmaceuticals's shares have ranged in value from as little as $6.32 up to $23.98. A popular way to gauge a stock's volatility is its "beta".

SNDX.US volatility(beta: 1.7)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Syndax Pharmaceuticals's is 1.6984. This would suggest that Syndax Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Syndax Pharmaceuticals overview

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates are entinostat that is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 in Phase I/II clinical trial inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. It also develops entinostat with Keytruda (pembrolizumab) in a Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and melanoma or microsatellite stable colorectal carcinoma; and with Tecentriq (atezolizumab) in Phase Ib/II clinical trials to treat patients with HR+ and HER2- metastatic breast cancer. In addition, the company develops SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 that is in Phase I/II clinical trial in patients with chronic graft versus host disease; and as a monotherapy and in combination with Imfinzi (durvalumab), which is completed Phase Ib dose trials for the treatment of solid tumors. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH; Genentech, Inc.; and Merck KGaA and Pfizer. It also has collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site